{"id":77533,"date":"2026-08-31T14:15:44","date_gmt":"2026-08-31T06:15:44","guid":{"rendered":"https:\/\/flcube.com\/?p=77533"},"modified":"2026-08-31T14:15:44","modified_gmt":"2026-08-31T06:15:44","slug":"simnova-closes-nearly-rmb-400-million-series-b-to-advance-car-nk-candidate-snc103","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77533","title":{"rendered":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simnova Biotech<\/strong> announced the completion of a <strong>Series B financing round<\/strong> of nearly <strong>RMB 400 million<\/strong>, co\u2011led by <strong>Fortera Capital<\/strong>, <strong>Cenova Capital<\/strong>, and <strong>Pudong Venture Capital<\/strong>, with participation from <strong>Zhangke Herun<\/strong> and <strong>Oriza Holdings<\/strong>, and follow\u2011on investment from existing shareholder <strong>Youshan Capital<\/strong>. Proceeds will accelerate confirmatory clinical trials of <strong>SNC103<\/strong>, the company&#8217;s core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate <strong>SNC116<\/strong> into registrational clinical development.<\/p>\n\n\n\n<h2 id=\"h-financing-milestone\" class=\"wp-block-heading\">Financing Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>Simnova<\/strong><\/td><\/tr><tr><td>Round<\/td><td>Series B (~RMB 400 million)<\/td><\/tr><tr><td>Co\u2011Lead Investors<\/td><td><strong>Fortera Capital<\/strong>, <strong>Cenova Capital<\/strong>, <strong>Pudong Venture Capital<\/strong><\/td><\/tr><tr><td>Participating Investors<\/td><td><strong>Zhangke Herun<\/strong>, <strong>Oriza Holdings<\/strong>; follow\u2011on from <strong>Youshan Capital<\/strong><\/td><\/tr><tr><td>Date<\/td><td>31 Aug 2026<\/td><\/tr><tr><td>Use of Proceeds<\/td><td>Confirmatory trials for SNC103; registrational development of SNC116<\/td><\/tr><tr><td>Next Steps<\/td><td>Advance core CAR\u2011NK and in vivo CAR\u2011T candidates toward late\u2011stage clinical milestones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-technology-platforms\" class=\"wp-block-heading\">Company Profile &amp; Technology Platforms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2019, originated as the cell therapy unit of <strong>Simcere Pharmaceutical<\/strong>; operating independently since 2021<\/li>\n\n\n\n<li><strong>Focus:<\/strong> Next\u2011generation cell therapies across autoimmune and oncology indications<\/li>\n\n\n\n<li><strong>Platform 1:<\/strong> Off\u2011the\u2011shelf CAR\u2011NK \u2014 allogeneic, readily available cell therapy format<\/li>\n\n\n\n<li><strong>Platform 2:<\/strong> In vivo CAR\u2011T \u2014 next\u2011generation approach engineering T cells inside the body<\/li>\n\n\n\n<li><strong>Platform 3:<\/strong> Multi\u2011targeted solid tumor CAR\u2011T<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-snc103-in-sle\" class=\"wp-block-heading\">Clinical Evidence \u2013 SNC103 in SLE<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Candidate<\/td><td><strong>SNC103<\/strong>, CD19\u2011targeted CAR\u2011NK therapy<\/td><\/tr><tr><td>Indication<\/td><td>Moderate\u2011to\u2011severe systemic lupus erythematosus (SLE)<\/td><\/tr><tr><td>Phase I Outcome<\/td><td>Positive results with best\u2011in\u2011class potential<\/td><\/tr><tr><td>Key Efficacy Signal<\/td><td>100% SRI\u20114 (SLE Responder Index\u20114) response rate<\/td><\/tr><tr><td>Comparator<\/td><td>Off\u2011the\u2011shelf positioning vs. autologous CAR\u2011T regimens in autoimmune disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">SNC103&#8217;s Phase I data in moderate\u2011to\u2011severe SLE \u2014 anchored by a 100% SRI\u20114 response rate \u2014 positions the candidate among the most compelling early readouts in the rapidly growing field of cell therapies for autoimmune disease. Its off\u2011the\u2011shelf CAR\u2011NK format could offer meaningful practical and cost advantages over personalized autologous CAR\u2011T approaches.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Cell Therapy Momentum:<\/strong> SLE has become one of the hottest frontiers in cell therapy, with CAR\u2011based approaches showing transformative remission potential<\/li>\n\n\n\n<li><strong>Off\u2011the\u2011Shelf Advantage:<\/strong> Allogeneic CAR\u2011NK could improve scalability and accessibility relative to bespoke CAR\u2011T manufacturing<\/li>\n\n\n\n<li><strong>Platform Breadth:<\/strong> In vivo CAR\u2011T and solid tumor programs diversify risk beyond the lead autoimmune candidate<\/li>\n\n\n\n<li><strong>Strategic Lineage:<\/strong> Simnova&#8217;s origin within Simcere Pharmaceutical provides established pharmaceutical infrastructure and credibility in China&#8217;s biotech ecosystem<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding Simnova&#8217;s clinical development, regulatory progress, and commercialization of SNC103 and SNC116. Actual results may differ materially due to risks inherent in drug development, regulatory review, manufacturing, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77535,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[21,77,20,3260],"class_list":["post-77533","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-car-t","tag-cell-therapy","tag-finance","tag-simnova-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company&#039;s core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77533\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103\" \/>\n<meta property=\"og:description\" content=\"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company&#039;s core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77533\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T06:15:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103\",\"datePublished\":\"2026-08-31T06:15:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533\"},\"wordCount\":455,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3104.webp\",\"keywords\":[\"CAR-T\",\"Cell-therapy\",\"Finance\",\"Simnova Biotech\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77533#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77533\",\"name\":\"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3104.webp\",\"datePublished\":\"2026-08-31T06:15:44+00:00\",\"description\":\"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company's core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77533\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simnova Closes ~RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77533#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103 - Insight, China&#039;s Pharmaceutical Industry","description":"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company's core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77533","og_locale":"en_US","og_type":"article","og_title":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103","og_description":"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company's core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.","og_url":"https:\/\/flcube.com\/?p=77533","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T06:15:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77533#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77533"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103","datePublished":"2026-08-31T06:15:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77533"},"wordCount":455,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77533#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","keywords":["CAR-T","Cell-therapy","Finance","Simnova Biotech"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77533#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77533","url":"https:\/\/flcube.com\/?p=77533","name":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77533#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77533#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","datePublished":"2026-08-31T06:15:44+00:00","description":"Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400 million, co\u2011led by Fortera Capital, Cenova Capital, and Pudong Venture Capital, with participation from Zhangke Herun and Oriza Holdings, and follow\u2011on investment from existing shareholder Youshan Capital. Proceeds will accelerate confirmatory clinical trials of SNC103, the company's core off\u2011the\u2011shelf CAR\u2011NK therapy, and advance its in vivo CAR\u2011T platform candidate SNC116 into registrational clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77533#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77533"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77533#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","width":1080,"height":608,"caption":"Simnova Closes ~RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77533#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simnova Closes nearly RMB 400 Million Series B to Advance CAR\u2011NK Candidate SNC103"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3104.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77533"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77533\/revisions"}],"predecessor-version":[{"id":77536,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77533\/revisions\/77536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77535"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}